In 2018 and 2019, researchers published two studies demonstrating the pivotal function of IL-1 in the development of two of the most common side effects of T cell-based therapies: cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS) [65,66]. The gene discussed is IL1A; the disease is congenital rubella syndrome.